Search

Displaying results 4451 - 4460 of 10000 in total
  1. Drug

    Amubarvimab

    go.drugbank.com/drugs/DB16493
    Investigational

    Amubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.

  2. Drug

    Piclamilast

    go.drugbank.com/drugs/DB01791
    Experimental

    The structure for piclamilast was first elucidated in a 1995 European patent application and exhibits the structural functionalities of cilomilast and roflumilast. … It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma.

    Synonyms: 3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-p-anisamide, 3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxybenzamide
  3. Drug

    Technetium Tc-99m ciprofloxacin

    go.drugbank.com/drugs/DB05488
    Experimental

    99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging agent for the potential diagnosis of infection, including fever of unknown origin, osteomyelitis … INFECTON combines the widely used antibiotic, ciprofloxacin, with Technetium ((99m)Tc), the most commonly used radioisotope in nuclear medical imaging There is currently controversy around the drug's ability

  4. Drug

    Goralatide

    go.drugbank.com/drugs/DB20748
    Experimental

    Goralatide has a monoisotopic molecular weight of 487.23 Da.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Copper Cu-64

    go.drugbank.com/drugs/DB13980
    Approved

    Copper-64 is a radiopharmaceutical usually found in the +2 oxidation state as the complexes including the +1 state tend to be more unstable. … [T604] It is used in molecular radiotherapy and positron emission tomography.

  6. Drug

    Cintredekin besudotox

    go.drugbank.com/drugs/DB05305
    Investigational

    The IL13 portion binds to receptors on the tumor. … Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual

  7. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in vitro. … It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease).

  8. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    [L56065] Navepegritide was approved by the US FDA in February 2026 for use in patients 2 years of age and older with achondroplasia with open epiphyses.[L56058,L56065] … endochondral ossification, resulting in multisystem complications including short stature.

  9. Drug

    Chlorotoxin I-131

    go.drugbank.com/drugs/DB05462
    Investigational

    The synthetic version of this peptide has been manufactured and covalently linked to iodine 131 as a means of targeting radiation to tumor cells in the treatment of brain cancer. … Chlorotoxin I-131 is investigated in clinical trials for treating brain cancer.

  10. Drug

    AS1409

    go.drugbank.com/drugs/DB05182
    Investigational

    One is the cytokine IL12, which has anti-cancer activity. The other is an antibody that targets tumours. … It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and melanoma.